OMC
61
6
NTAP
66
2
ACN
49
2
AEE
64
4
FMC
33
2
GPC
37
2
THC
55
-4
HOG
33
4
PWR
72
2
OKE
81
3
EXPD
45
8
PCAR
56
3
CTSH
54
-2
QRVO
8
4
PNR
69
4
PLD
48
-5
BF.B
31
3
KHC
11
2
ROK
47
-8
CPB
24
2
OMC
61
6
NTAP
66
2
ACN
49
2
AEE
64
4
FMC
33
2
GPC
37
2
THC
55
-4
HOG
33
4
PWR
72
2
OKE
81
3
EXPD
45
8
PCAR
56
3
CTSH
54
-2
QRVO
8
4
PNR
69
4
PLD
48
-5
BF.B
31
3
KHC
11
2
ROK
47
-8
CPB
24
2
Financhill
Back

Lyell Immunopharma 10K Form

Sell
9

LYEL
Lyell Immunopharma

Last Price:
0.95
Seasonality Move:
-22.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LYEL News And Ratings

See the #1 stock for the next 7 days that we like better than LYEL

LYEL Financial Statistics

Sales & Book Value

Annual Sales: $130K
Cash Flow: $-35.1M
Price / Cash Flow: 0
Annual Sales: $2.07
Price / Book: 0.48

Profitability

EPS (TTM): -0.79000
Net Income (TTM): $-203.99M
Gross Margin: --
Return on Equity: -33.41%
Return on Assets: -29.04%

Lyell Immunopharma Earnings Forecast

Key Lyell Immunopharma Financial Ratios

  • The Research & Development expenses have been 140,726.92% of Revenue.
  • The Net Earning history of LYEL is -180,486.15% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Lyell Immunopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LYEL
Website: lyell.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 13.43
Quick Ratio: 13.15

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LYEL Technical Analysis vs Fundamental Analysis

Sell
9
Lyell Immunopharma (LYEL) is a Sell

Is Lyell Immunopharma a Buy or a Sell?